Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Ensemble, Genentech Collaborate on Macrocycle Drugs

By Drug Discovery Trends Editor | June 5, 2012

Ensemble Therapeutics, a biotechnology company developing Ensemblins, a novel class of small molecule therapeutics with the power of biologics,  announced the initiation of a drug discovery collaboration with Genentech, a member of the Roche Group, to discover macrocyclic drug candidates against targets specified by Genentech.

The collaboration will deploy Ensemble’s proprietary drug discovery platform, including its Ensemblin collection of over 5 million macrocycles, to discover novel drug candidates against Genentech’s drug targets. Genentech will have the right to develop and commercialize lead molecules arising from the collaboration.

Under the terms of the agreement, Ensemble will receive an undisclosed upfront payment and milestone payments upon the successful achievement of certain development milestones.  In addition, Ensemble is eligible to receive royalties on future sales of products that arise from the collaboration.

“This collaboration further validates the wide-ranging potential of our Ensemblin drug discovery platforms while providing Ensemble with additional resources to advance our own internal pipeline,” said Dr. Michael D. Taylor, CEO of Ensemble Therapeutics.

James Sabry, Genentech’s Vice President of Partnering, said, “We believe Ensemble’s approach to develop macrocyclic small molecules to address drug discovery targets that have proven difficult to modulate with traditional approaches could result in innovative new medicines.”

The collaboration with Genentech builds on Ensemble’s business model to partner with drug development leaders, with this as the third collaboration with a major pharmaceutical company, to leverage the Ensemblin discovery engine to identify novel macrocyclic drug candidates.

Date: May 29, 2012
Source: Ensemble Therapeutics


Filed Under: Drug Discovery

 

Related Articles Read More >

If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
Physician in a white coat reviewing information on a tablet with a patient in an exam room.
What real-world data shows about current cancer care
Roche Towers, Basel, Switzerland
Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE